Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2019 Filed Mar 7, 2019 21:15 UTC |
Berger Mark StanleyChief Medical Officer
|
OtherCommon Stock | 3,500 | $0.60 | $2,100.00 |
DisclosureSEC source: 0001213900-19-003738 · ownership.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Read SEC document |
| February 21, 2019 Filed Feb 21, 2019 21:45 UTC |
SETH SANDESHDirector · Chairman & CEO
|
OtherCommon Stock | 8,125 | $0.60 | $4,875.00 |
DisclosureSEC source: 0001213900-19-002982 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,458 Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 21:14 UTC |
SETH SANDESHDirector · Chairman & CEO
|
PurchaseCommon Stock | 10,000 | $0.44 | $4,372.00 |
DisclosureSEC source: 0001213900-18-017145 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,333 Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 21:10 UTC |
O'Loughlin StevePrincipal Financial Officer
|
PurchaseCommon Stock | 10,000 | $0.44 | $4,350.00 |
DisclosureSEC source: 0001213900-18-017143 · ownership.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 22:08 UTC |
Ludwig Dale L.Chief Scientific Officer
|
PurchaseCommon Stock | 10,000 | $0.45 | $4,499.00 |
DisclosureSEC source: 0001213900-18-016321 · ownership.xml · nonDerivative · entry 1 Ludwig Dale L. · CIK 0001727406 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 21:13 UTC |
SETH SANDESHDirector · CEO
|
PurchaseCommon stock | 10,000 | $0.79 | $7,900.00 |
DisclosureSEC source: 0001213900-18-009317 · ownership.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,333 Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 17:10 UTC |
Shetty AjitDirector
|
GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009314 · ownership.xml · derivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:04 UTC |
Steinhart Richard IDirector
|
GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009311 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:19 UTC |
Nicholson, C. DavidDirector
|
GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009327 · ownership.xml · derivative · entry 1 Nicholson, C. David · CIK 0001636168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:18 UTC |
Chell Jeffrey W.Director
|
GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009325 · ownership.xml · derivative · entry 1 Chell Jeffrey W. · CIK 0001738374 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:17 UTC |
Ray Nitya G.Executive VP
|
GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009324 · ownership.xml · derivative · entry 1 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:15 UTC |
Berger Mark StanleyChief Medical Officer
|
GrantOptions to purchase common stock · Derivative | 250,000 | $0.78 Strike: $0.78 | $195,725.00 |
DisclosureSEC source: 0001213900-18-009320 · ownership.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:13 UTC |
SETH SANDESHDirector · CEO
|
GrantOptions to purchase common stock · Derivative | 1,000,000 | $0.78 Strike: $0.78 | $782,900.00 |
DisclosureSEC source: 0001213900-18-009317 · ownership.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:11 UTC |
O'Loughlin StevePrincipal Financial Officer
|
GrantOptions to purchase common stock · Derivative | 265,000 | $0.78 Strike: $0.78 | $207,468.50 |
DisclosureSEC source: 0001213900-18-009315 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 22:08 UTC |
O'Loughlin StevePrincipal Financial Officer
|
PurchaseCommon Stock | 12,000 | $0.50 | $6,000.00 |
DisclosureSEC source: 0001213900-18-007754 · f4061518oloughlin_actinium.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 20:15 UTC |
SETH SANDESHDirector · Chairman & CEO
|
PurchaseCommon Stock | 5,000 | $0.38 | $1,900.00 |
DisclosureSEC source: 0001213900-18-004773 · f4041918seth_actiniumpharma.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:24 UTC |
Steinhart Richard IDirector
|
OtherSeries B Warrants · Derivative | 5,250 | $0.50 Strike: $0.70 | $2,625.00 |
DisclosureSEC source: 0001213900-18-002730 · f4030618steinhart_actinium.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:24 UTC |
Steinhart Richard IDirector
|
OtherSeries A Warrants · Derivative | 1,750 | $0.50 Strike: $0.60 | $875.00 |
DisclosureSEC source: 0001213900-18-002730 · f4030618steinhart_actinium.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:24 UTC |
Steinhart Richard IDirector
|
OtherCommon Stock | 7,000 | $0.50 | $3,500.00 |
DisclosureSEC source: 0001213900-18-002730 · f4030618steinhart_actinium.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:35 UTC |
SETH SANDESHDirector · Chairman & CEO
|
OtherSeries B Warrants · Derivative | 39,375 | $0.50 Strike: $0.70 | $19,687.50 |
DisclosureSEC source: 0001213900-18-002739 · f4030618seth_actiniumpharm.xml · derivative · entry 3 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:35 UTC |
SETH SANDESHDirector · Chairman & CEO
|
OtherSeries A Warrants · Derivative | 13,125 | $0.50 Strike: $0.60 | $6,562.50 |
DisclosureSEC source: 0001213900-18-002739 · f4030618seth_actiniumpharm.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:35 UTC |
SETH SANDESHDirector · Chairman & CEO
|
OtherCommon Stock | 52,500 | $0.50 | $26,250.00 |
DisclosureSEC source: 0001213900-18-002739 · f4030618seth_actiniumpharm.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,333 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:32 UTC |
Ray Nitya G.Executive VP
|
OtherSeries B Warrants · Derivative | 7,500 | $0.50 Strike: $0.70 | $3,750.00 |
DisclosureSEC source: 0001213900-18-002737 · f4030618ray_actiniumpharm.xml · derivative · entry 3 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:32 UTC |
Ray Nitya G.Executive VP
|
OtherSeries A Warrants · Derivative | 2,500 | $0.50 Strike: $0.60 | $1,250.00 |
DisclosureSEC source: 0001213900-18-002737 · f4030618ray_actiniumpharm.xml · derivative · entry 2 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:32 UTC |
Ray Nitya G.Executive VP
|
OtherCommon Stock | 10,000 | $0.50 | $5,000.00 |
DisclosureSEC source: 0001213900-18-002737 · f4030618ray_actiniumpharm.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:20 UTC |
O'Loughlin StevePrincipal Financial Officer
|
OtherSeries B Warrants · Derivative | 7,500 | $0.50 Strike: $0.70 | $3,750.00 |
DisclosureSEC source: 0001213900-18-002726 · f4030618oloughlin_actinium.xml · derivative · entry 3 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:20 UTC |
O'Loughlin StevePrincipal Financial Officer
|
OtherSeries A Warrants · Derivative | 2,500 | $0.50 Strike: $0.60 | $1,250.00 |
DisclosureSEC source: 0001213900-18-002726 · f4030618oloughlin_actinium.xml · derivative · entry 2 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:20 UTC |
O'Loughlin StevePrincipal Financial Officer
|
OtherCommon Stock | 10,000 | $0.50 | $5,000.00 |
DisclosureSEC source: 0001213900-18-002726 · f4030618oloughlin_actinium.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| March 06, 2018 Filed Mar 19, 2018 21:04 UTC |
Berger Mark StanleyChief Medical Officer
|
OtherSeries B Warrants · Derivative | 10,500 | $0.50 Strike: $0.70 | $5,250.00 |
DisclosureSEC source: 0001213900-18-003155 · f4030618berger_actinium.xml · derivative · entry 3 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 19, 2018 21:04 UTC |
Berger Mark StanleyChief Medical Officer
|
OtherSeries A Warrants · Derivative | 3,500 | $0.50 Strike: $0.60 | $1,750.00 |
DisclosureSEC source: 0001213900-18-003155 · f4030618berger_actinium.xml · derivative · entry 2 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 19, 2018 21:04 UTC |
Berger Mark StanleyChief Medical Officer
|
OtherCommon Stock | 14,000 | $0.50 | $7,000.00 |
DisclosureSEC source: 0001213900-18-003155 · f4030618berger_actinium.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 07:08 UTC |
Shetty AjitDirector
|
PurchaseCommon stock | 22,730 | $0.43 | $9,773.90 |
DisclosureSEC source: 0001213900-18-002433 · f4022818shetty_actiniumpharm.xml · nonDerivative · entry 1 Shetty Ajit · CIK 0001667471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,730 Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 20:35 UTC |
SETH SANDESHDirector · Chairman & CEO
|
PurchaseCommon Stock | 33,333 | $0.75 | $24,999.75 |
DisclosureSEC source: 0001213900-17-008254 · f4080217seth_actiniumpharm.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,833 Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 20:22 UTC |
Ray Nitya G.Executive Vice President
|
PurchaseCommon Stock | 10,000 | $0.75 | $7,500.00 |
DisclosureSEC source: 0001213900-17-008246 · f4080217ray_actiniumpharm.xml · nonDerivative · entry 1 Ray Nitya G. · CIK 0001709522 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:56 UTC |
Berger Mark StanleyChief Medical Officer
|
PurchaseCommon stock | 5,000 | $1.11 | $5,550.00 |
DisclosureSEC source: 0001213900-17-006531 · f4061517berger_actinium.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:54 UTC |
SETH SANDESHDirector · Chairman and CEO
|
PurchaseCommon Stock | 5,000 | $1.16 | $5,800.00 |
DisclosureSEC source: 0001213900-17-006529 · f4061517seth_actinium.xml · nonDerivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:54 UTC |
SETH SANDESHDirector · Chairman and CEO
|
PurchaseCommon stock | 2,500 | $1.17 | $2,925.00 |
DisclosureSEC source: 0001213900-17-006529 · f4061517seth_actinium.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:51 UTC |
O'Loughlin StevePrincipal Financial Officer
|
PurchaseCommon stock | 3,500 | $1.17 | $4,095.00 |
DisclosureSEC source: 0001213900-17-006527 · f4061517oloughlin_actinium.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:10 UTC |
Steinhart Richard IDirector
|
GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002453 · f4031417steinhart_actinium.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:18 UTC |
DAVE KAUSHIK JDirector · CEO and Interim CFO
|
GrantOptions to purchase common stock · Derivative | 250,000 | $1.39 Strike: $1.39 | $347,500.00 |
DisclosureSEC source: 0001213900-17-002501 · f4031417dave_actinium.xml · derivative · entry 1 DAVE KAUSHIK J · CIK 0001522751 · Director · CEO and Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:35 UTC |
TRAVERSA SERGIODirector
|
GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002467 · f4031417traversa_actinium.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC |
SETH SANDESHDirector · Executive Chairman
|
GrantOptions to purchase common stock · Derivative | 750,000 | $1.39 Strike: $1.39 | $1,042,500.00 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 5 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2027-03-14 F3 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC |
SETH SANDESHDirector · Executive Chairman
|
GrantWarrant to purchase common stock · Derivative | 57,212 | $2.34 Strike: $2.34 | $133,876.08 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 4 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,212 Underlying: Common Stock · 57.212 shares Expires 2022-02-11 Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC |
SETH SANDESHDirector · Executive Chairman
|
OtherWarrant to purchase common stock · Derivative | 57,212 | $2.34 Strike: $2.34 | $133,876.08 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 3 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,212 shares Expires 2018-01-28 F2 · kind: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for these latter services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14, 2017 the Company cancelled a Warrant in the amount of 57,212, shares and issued a new warrant with a term until February 11, 2022. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC |
SETH SANDESHDirector · Executive Chairman
|
OtherWarrant to purchase common stock · Derivative | 99,619 | $0.78 Strike: $0.78 | $77,702.82 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 2 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 99.619 Underlying: Common Stock · 99,619 shares Expires 2022-02-11 F1 · kind: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family. F1 · ownership.nature: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:36 UTC |
SETH SANDESHDirector · Executive Chairman
|
OtherWarrant to purchase common stock · Derivative | 64,746 | $0.78 Strike: $0.78 | $50,501.88 |
DisclosureSEC source: 0001213900-17-002469 · f4031417sandesh_actinium.xml · derivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,746 Underlying: Common Stock · 64.746 shares Expires 2022-02-11 F1 · kind: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:33 UTC |
Nicholson, C. DavidDirector
|
GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002465 · f4031417nicholson_actinium.xml · derivative · entry 1 Nicholson, C. David · CIK 0001636168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:07 UTC |
CICIC DRAGANChief Technology Officer
|
GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002450 · f4031417cicic_actinium.xml · derivative · entry 1 CICIC DRAGAN · CIK 0001565795 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 13:00 UTC |
SETH SANDESHDirector · Executive Chairman
|
PurchaseCommon stock | 5,000 | $0.88 | $4,400.00 |
DisclosureSEC source: 0001213900-17-000008 · f4123016seth_actiniumphar.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Read SEC document |
| December 12, 2016 Filed Dec 12, 2016 21:44 UTC |
SETH SANDESHDirector · Executive Chairman
|
PurchaseCommon stock | 5,000 | $0.98 | $4,900.00 |
DisclosureSEC source: 0001213900-16-019329 · f4121216sandesh_actiniumphar.xml · nonDerivative · entry 1 SETH SANDESH · CIK 0001566175 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.